PT-141 10mg dosage for women explained: how to reconstitute a 10 mg vial, the approved 1.75 mg injection amount, side effects, and key safety notes.
A 10 mg vial of PT-141 is a supply quantity, not a single dose. Bremelanotide, sold under the brand name Vyleesi, is FDA-approved for premenopausal women with hypoactive sexual desire disorder at a fixed 1.75 mg subcutaneous injection — roughly one-fifth of a 10 mg vial. How much liquid you actually draw depends entirely on how much bacteriostatic water you add.
Most PT-141 10mg dosage questions from women come down to three issues: reconstitution math, the approved 1.75 mg ceiling, and side effects. Here is how the numbers work in practice.
What Is Inside a 10 mg PT-141 Vial?
PT-141 (bremelanotide acetate) ships as a lyophilized powder in sealed vials intended for laboratory research. A 10 mg vial contains 10 milligrams of dry peptide that must be dissolved before any dose can be measured.
- Peptide content: 10 mg of bremelanotide per vial
- Form: freeze-dried powder, not a ready-to-use liquid
- Reconstitution fluid: bacteriostatic water or sterile water
- Storage: refrigerate after mixing and protect from light
Because the vial is dry, the 10 mg label says nothing about dose volume until you know the concentration. Concentration is set by how much water you add.
How to Reconstitute a 10 mg Vial for Women's Dosing
The math is straightforward: total milligrams divided by total milliliters of water equals milligrams per milliliter.
- 1 mL of water → 10 mg/mL (very concentrated)
- 2 mL of water → 5 mg/mL (the most common choice)
- 5 mL of water → 2 mg/mL (easier to read, larger injection volume)
At 5 mg/mL, the approved 1.75 mg dose equals 0.35 mL, or 35 units on a U-100 insulin syringe. That single number is the reference point behind most pt-141 injection dosage discussions for women.
Dose Volume by Reconstitution Volume (10 mg Vial)
| Water added | Concentration | 0.5 mg | 1 mg | 1.75 mg (approved) | 2 mg |
|---|---|---|---|---|---|
| 1 mL | 10 mg/mL | 0.05 mL (5 units) | 0.10 mL (10 units) | 0.175 mL (17.5 units) | 0.20 mL (20 units) |
| 2 mL | 5 mg/mL | 0.10 mL (10 units) | 0.20 mL (20 units) | 0.35 mL (35 units) | 0.40 mL (40 units) |
| 5 mL | 2 mg/mL | 0.25 mL (25 units) | 0.50 mL (50 units) | 0.875 mL (87.5 units) | 1.00 mL (100 units) |
Units assume a U-100 insulin syringe. A 1.75 mg dose is the only strength with FDA approval for women, and it is sold as a single-use auto-injector pen rather than a vial. Anything above the 1.75 mg line is off-label or research use.
PT-141 is FDA-approved as Vyleesi at a fixed 1.75 mg subcutaneous dose for premenopausal women, given no more than once every 24 hours.
Injection vs. Nasal Spray vs. Oral PT-141
Route of administration changes both the dose and the effect, and the routes are not interchangeable milligram for milligram.
| Route | Typical reported dose | FDA status | Notes |
|---|---|---|---|
| Subcutaneous injection | 1.75 mg | Approved (Vyleesi) | One dose per 24 hours, maximum eight doses per month |
| Nasal spray | 7.5–12.5 mg in early trials | Not approved | Far higher doses were required; absorption is inconsistent |
| Oral or sublingual | Not established | Not approved | Poor bioavailability |
Nasal PT-141 was studied years ago at doses much higher than the injectable, and the FDA never approved that formulation. Published pt 141 nasal spray dosage figures come from small early trials and do not describe a product you can legally buy.
Nasal and oral versions also cannot be compared to injections by milligram alone, so always confirm which route a dosing chart actually describes.
Side Effects and Safety for Women
Bremelanotide is not risk-free. The most frequently reported reaction is nausea, followed by flushing, headache, and injection-site irritation.
- Nausea and vomiting — most common, and dose-related
- Flushing and warmth in the face, neck, and chest
- Headache
- Injection site reactions and discomfort
- Transient increases in blood pressure
- Focal hyperpigmentation of the skin with repeated use
Nausea is the most consistent of the pt-141 for women side effects, and it tends to worsen as doses climb above the approved 1.75 mg. Bremelanotide is contraindicated in women with uncontrolled hypertension or known cardiovascular disease because it can raise blood pressure temporarily.
Vyleesi should not be used more than once in 24 hours or more than eight times per month. Women who are pregnant, breastfeeding, or taking blood pressure medication should speak with a healthcare professional before considering it.
Why the Vial Size Is Not the Dose
Some search results imply that a 10 mg vial means a 10 mg dose. That confuses supply with dose. A 10 mg vial reconstituted with 2 mL of water yields five to six approved 1.75 mg doses, not one large injection.
Male use is a separate subject entirely, because FDA approval covers premenopausal women only. Anyone reading about pt 141 dosage for men should treat those numbers as off-label and unverified.
Getting the Measurement Right
Steps that reduce dosing errors:
- Decide your reconstitution volume and calculate concentration first.
- Use a U-100 insulin syringe for small volumes.
- Write the concentration in mg/mL directly on the vial label.
- Recheck the math before every injection.
- Refrigerate after mixing and never reuse a needle.
Needle size, site rotation, and absorption are covered in more detail in our guide to pt-141 dosage subcutaneous. Timing matters as well: bremelanotide is normally injected about 45 minutes before activity, and eating beforehand can make nausea worse.
PT-141 is a prescription medicine in its approved form and a research chemical when sold as a vial, and those two categories carry very different levels of oversight. No dose drawn from a research vial has been reviewed for safety or purity, which is a real limitation no matter how carefully the math is done.
Frequently Asked Questions
How much PT-141 should a woman take from a 10 mg vial?
The FDA-approved dose of bremelanotide is 1.75 mg injected subcutaneously, which is not the same as the full contents of a 10 mg vial. If you reconstitute a 10 mg vial with 2 mL of bacteriostatic water, the concentration is 5 mg/mL, so 1.75 mg equals 0.35 mL — about 35 units on a U-100 insulin syringe. One 10 mg vial therefore contains roughly five to six approved female doses.
How do you reconstitute a PT-141 10 mg vial for women's dosing?
Add bacteriostatic water slowly down the inside wall of the vial instead of directly onto the powder, then swirl gently. Do not shake the vial, because agitation can damage the peptide. Using 2 mL of water gives a 5 mg/mL concentration, which is the easiest to measure accurately with a U-100 insulin syringe. Label the vial with the concentration and refrigerate it, protected from light.
Is PT-141 safe for women?
Bremelanotide is FDA-approved as Vyleesi for premenopausal women with hypoactive sexual desire disorder, so it has a documented safety profile at 1.75 mg. Common side effects include nausea, flushing, headache, and injection-site reactions, and it is contraindicated in women with uncontrolled high blood pressure or heart disease. Anyone with cardiovascular risk factors should talk to a healthcare professional before using it.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.